NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis $15.02 -0.46 (-2.97%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$15.02 0.00 (-0.03%) As of 09/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Mesoblast Stock (NASDAQ:MESO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mesoblast alerts:Sign Up Key Stats Today's Range$14.89▼$15.1750-Day Range$14.12▼$18.2452-Week Range$13.05▼$21.50Volume173,211 shsAverage Volume197,731 shsMarket Capitalization$1.95 billionP/E RatioN/ADividend YieldN/APrice Target$39.00Consensus RatingHold Company Overview Mesoblast Limited (NASDAQ: MESO) is a biotechnology company focused on developing and commercializing regenerative medicine products based on proprietary mesenchymal lineage stromal cells. The company’s cell therapies are designed to address serious inflammatory and immune-mediated conditions by potentially reducing inflammation, supporting tissue repair and modulating immune responses. Mesoblast’s lead product, remestemcel-L, is marketed in the United States as Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The therapy received approval from the U.S. Food and Drug Administration in 2024 and is the company’s first commercial product in the United States. Mesoblast has also investigated cell-based therapies for conditions including chronic heart failure, chronic low back pain and other inflammatory disorders. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast has conducted research and clinical development activities in the United States, Australia and other international markets. The company’s products and candidates have been developed through internal research programs and collaborations with pharmaceutical and healthcare organizations. Mesoblast is led by founder and Chief Executive Officer Silviu Itescu, who has overseen the company’s development of allogeneic cellular medicines.AI Generated. May Contain Errors. Read More Mesoblast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreMESO MarketRank™: Mesoblast scored higher than 44% of companies evaluated by MarketBeat, and ranked 712th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialMesoblast has a consensus price target of $39.00, representing about 159.7% upside from its current price of $15.02.Amount of Analyst CoverageMesoblast has only been the subject of 2 research reports in the past 90 days.Read more about Mesoblast's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.05) to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -53.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -53.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.00% of the float of Mesoblast has been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 13.49, which indicates bearish sentiment.Change versus previous monthShort interest in Mesoblast has recently increased by 4.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentMesoblast has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mesoblast this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MESO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MESO Stock News HeadlinesWhy brokers see 85% upside for this ASX biotech stockSeptember 4, 2026 | msn.comExperts tip these $3 billion ASX shares to deliver over 75% returnsSeptember 1, 2026 | msn.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Mesoblast Limited (MESO) Q4 2026 Earnings Call TranscriptAugust 27, 2026 | seekingalpha.comMesoblast Reports Substantial Revenue Growth to US$120MAugust 26, 2026 | globenewswire.comMesoblast earnings: Strong revenue growth and operational milestones in FY26August 26, 2026 | msn.comMesoblast to Outline 2026 Results and Pipeline Progress in Investor WebcastAugust 24, 2026 | tipranks.comMesoblast Issues 875,000 Unquoted Employee Incentive OptionsAugust 24, 2026 | tipranks.comSee More Headlines MESO Stock Analysis - Frequently Asked Questions How have MESO shares performed this year? Mesoblast's stock was trading at $18.04 at the start of the year. Since then, MESO shares have decreased by 16.7% and is now trading at $15.02. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) released its quarterly earnings data on Friday, July, 31st. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $34.45 million for the quarter. When did Mesoblast's stock split? Shares of Mesoblast reverse split on the morning of Friday, January 5th 2024.The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Top institutional investors of Mesoblast include Squarepoint Ops LLC (0.01%), Tobias Financial Advisors Inc. (0.01%) and GAMMA Investing LLC (0.01%). View institutional ownership trends. How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings7/31/2026Today9/15/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MESO's financial health is in the Green zone, according to TradeSmith. MESO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees108Year Founded2004Price Target and Rating Average Price Target for Mesoblast$39.00 High Price Target$39.00 Low Price Target$39.00 Potential Upside/Downside+159.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.19 Current Ratio2.43 Quick Ratio2.09 Sales & Book Value Annual Sales$120.25 million Price / Sales16.22 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book3.43Miscellaneous Outstanding Shares129,880,000Free Float105,459,000Market Cap$1.95 billion OptionableOptionable Beta2.12 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:MESO) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
